CMPI

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

15-12B - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

EFFECT - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

Kuros Biosciences AG ("Kuros" or the "Company"), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ:CMPI) by Regeneron Pharmaceuticals (NASDAQ:REGN). The completion triggers a $5 million milestone payment under a license agreement entered into by Kuros and Checkmate in 2015. Under a royalty purchase agreement entered into by Kuros and XOMA Corporation (NASDAQ:XOMA) in 2021, XOMA is entitled to receive 50% of the milestone payment paid to Kuros as a result of a change of control of Checkmate Pharmaceuticals. Therefore, $2.5 million of the $5 million milestone due to Kuros under the 2015 license agreement will be p

25-NSE - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

S-8 POS - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

POS AM - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)

8-K - Checkmate Pharmaceuticals, Inc. (0001651431) (Filer)